operator installs a chromatography column to purify the gene therapy drug Glybera

Entering the Age of the $1 Million Medicine

By Ben Hirschler | Jan 03, 2013 10:09 AM EST

The Western world's first drug to fix faulty genes promises to transform the lives of patients with an ultra-rare disease that clogs their blood with fat.

man using smart phone

UK Dials Up "Virtual Doctors" in Big Telehealth Push

By Ben Hirschler | Dec 06, 2012 10:16 AM EST

British health minister announced plans to roll out telehealth to 100,000 people with long-term conditions in 2013 and have 3 million on the system by 2017.

Diabetes Cases Hit Record and Half Go Undiagnosed

By Ben Hirschler | Nov 14, 2012 09:44 AM EST

Diabetes is running at record levels worldwide and half the people estimated to have the disease are, as yet, undiagnosed.

Europe Approves High-Price Gene Therapy

By Ben Hirschler | Nov 02, 2012 10:30 AM EDT

European officials have approved the Western world's first gene therapy drug in a milestone for the novel medical technology that fixes faulty genes.

French Study Finds Tumors in Rats Fed GM Corn

By Ben Hirschler | Sep 19, 2012 09:53 AM EDT

Rats fed a lifetime diet of Monsanto's genetically modified corn or exposed to its top-selling weedkiller Roundup suffered tumours and multiple organ damage.

Painful Birth for Europe's New One-stop Patent

By Ben Hirschler | Aug 30, 2012 10:40 AM EDT

That Europe needs a common patent is patently obvious to Michael Setton, who runs a tiny technology firm in France making wireless sensors that track environmental and biomedical data.

Big Bets Aim to Jolt Heart Drug Sales Back to Life

By Ben Hirschler | Aug 29, 2012 09:41 AM EDT

The expiry of patents on profitable heart medicines is soon going to erode one of the main sources of drug company profits, and risky bets on new medicines to replace them may not make up for the lost sales.

UK to Review Cosmetic Surgery Industry

By Ben Hirschler | Aug 15, 2012 10:26 AM EDT

Britain has launched a review of the cosmetic surgery industry, which could lead to tighter restrictions on the way companies operate and market their services in the wake of the PIP breast implant scandal.

AstraZeneca Tries New Tack in Brain Research

By Ben Hirschler | Jul 12, 2012 12:36 PM EDT

AstraZeneca Plc has clinched two new deals in neuroscience, underlining the drugmaker's increasing reliance on external projects to refill a sparse pipeline as it tests a new low-cost approach to drug research.

Real Time Analytics